干扰性疟疾疫苗的研究进展

doi:10.11853/j.issn.1003.4692.2015.01.030

摘要/Abstract

摘要：

疟疾仍然是严重危害人类健康的传染性疾病之一,随着疫苗和佐剂的研究进展,疟疾疫苗的研发与应用面临着巨大机遇,现就干扰性疟疾疫苗的研究进展进行简要综述,并从候选疫苗面临的问题、安全性和抗原免疫原性等方面介绍干扰性疟疾疫苗的现状,为进一步优化干扰性疟疾疫苗的研究提供参考。

关键词: 疟疾, 传播阻断疫苗, 免疫, 恶性疟原虫子孢子囊表面膜蛋白, 间日疟原虫蛋白25, 干扰性疟疾疫苗

Abstract:

Malaria remains one of the infectious diseases endangering human health. With the development of vaccines and adjuvants, the study and application of malaria vaccines faces enormous opportunities. This review summarizes advances in the study of malaria vaccines and discusses the current status of candidate malaria vaccines in terms of the problems faced, safety, antigen immunogenicity, and so on, to provide a reference for the study on optimization of malaria vaccines.

Key words: Malaria, Transmission-blocking vaccine, Immunity, Plasmodium falciparum surface protein, Plasmodium vivax protein 25, Malaria vaccine

中图分类号:

R531.3

刘倩颖, 孙立新. 干扰性疟疾疫苗的研究进展[J]. 中国媒介生物学及控制杂志, 2015, 26(1): 104-107.

LIU Qian-ying, SUN Li-xin. Progress in research on transmission-blocking malaria vaccines[J]. Chines Journal of Vector Biology and Control, 2015, 26(1): 104-107.

参考文献

[1] World Health Organization. World malaria report 2013[EB/OL].[2014-09-01]. http://www.who.int/malaria/publications/world_ malaria_report_2013/en/.
[2] The malERA consultative group on vaccines 2011. a research agenda for malaria eradication:vaccines[J]. PLoS Med,2011,8 (1):e1000398. doi:10.1371/journal.pmed.1000398.
[3] Mendis K,Sina BJ,Marchesini P,et al. The neglected burden of Plasmodium vivax malaria[J]. Am J Trop Med Hyg,2001, 64:97-106.
[4] Arakawa T,Tsuboi T,Sattabongkot J,et al. Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potenttransmission-blocking immunity[J]. Clin Vaccine Immunol,2014,21(4):561-569.
[5] Sauerwein RW. Malaria transmission-blocking vaccines:the bonus of effective malaria control[J]. Microbes Infect,2007,12 (6):792-795.
[6] Carter R. Transmission blocking malaria vaccines[J]. Vaccine, 2001,19(17/19):2309-2314.
[7] Shimp RL Jr,Rowe C,Reiter K,et al. Development of a pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle[J]. Vaccine,2013,31(28): 2954-2962.
[8] Kaslow DC,Quakyi IA,Syin C,et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains[J]. Nature,1988,333(6168):74-76.
[9] Nirbhay K. A vaccine to prevent transmission of human malaria: a long way to travel on duaty and often bumpy road[J]. Curr Sci, 2007,92(11):1535-1543.
[10] 陈勇,雷清,刘晓,等. 恶性疟原虫膜蛋白Pfs25在毕赤酵母中的组成型表达[J]. 生物技术通讯,2011,22(6):785-788.
[11] Gregory JA,Li FW,Tomosada LM,et al. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission[J]. PLoS One,2012,7(5):e37179. doi: 10.1371/journal.pone.0037179.
[12] Duffy PE,Pimenta P,Kaslow DC. Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies[J]. J Exp Med,1993,177(2): 505-510.
[13] Gozar MMG,Muratova O, Keister DB,et al. Plasmodium falciparum:immunogenicity of alum-adsorbed clinical-grade TBV25-28,a yeast-secreted malaria transmission-blocking vaccine candidate[J]. Exp Parasitol,2001,97(2):61-69.
[14] Tomas AM,Margos G,Dimopoulos G,et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions[J]. EMBOJ,2001,20(15): 3975-3983.
[15] Malkin EM,Durbin AP,Diemert DJ,et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria[J]. Vaccine,2005,23(24) : 3131-3138.
[16] Miao J,Fan Q,Parker D,et al. Puf mediates translation repression of transmission-blocking vaccine candidates in malaria parasites[J]. PLoS Pathog,2013,9(4):e1003268. doi: 10.1371/journal.ppat.1003268.
[17] Feng H,Zheng L,Zhu XT, et al. Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan province,China[J]. Parasit Vectors,2011,4:224.
[18] Hisaeda H,Stowers AW,Tsuboi T,et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes[J]. Infect Immun, 2000,68(12):6618-6623.
[19] Barr TA,Carlring J,Heath AW. Co-stimulatory agonists as immunological adjuvants[J]. Vaccine,2006,24(17):3399-3407.
[20] Barr PJ,Green KM,Gibson HL,et al. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals[J]. J Exp Med, 1991,174(5):1203-1208.
[21] Wu YM,Ellis RD,Shaffer D,et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51[J]. PLoS One,2008,3(7): e2636. doi: 10.1371/journal.pone.0002636.
[22] Qian F,Wu Y,Muratova O,et al. Con-jugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A:a strategy for enhancing immunogenicity of malaria vaccine candidates[J]. Vaccine,2007,25(20):3923-3933.
[23] Kubler-Kielb J,Majadly F,Wu Y,et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25[J]. Proc Natl Acad Sci USA,2007,104(1):293-298.
[24] Wu Y,Przysiecki C,Flanagan E,et al. Sustained high-titer antibody responses induced by conjugating a malarial vac-cine candidate to outer-membrane protein complex[J]. Proc Natl Acad Sci USA,2006,103(48):18243-18248.
[25] Miyata T,Harakuni T,Sugawa H,et al. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine[J]. Vaccine,2011,29 (15):2720-2726.
[26] Alonso PL,Sacarlal J,Aponte JJ,et al. Efficacy of the RTS,S/ AS02A vaccine against Plasmodium falciparum infection and disease in young African children:randomised controlled trial[J]. Lancet,2004,364(9443):1411-1420.
[27] Alonso PL,Sacarlal J,Aponte JJ,et al. Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:single-blind extended follow-up of a randomised controlled trial[J]. Lancet,2005,366(9502):2012-2018.
[28] Dinglasan RR,Kalume DE,Kanzok SM,et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen[J]. Proc Natl Acad Sci USA, 2007,104(3):13461-13466.
[29] Foy BD,Magalhaes T,Injera WE,et al. Induction of mosquitocidal activity in mice immunized with Anopheles gambiae midgut cDNA[J]. Infect Immun,2003,71(4):2032-2040.
[30] Kimani D,Jagne YJ,Cox M,et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations[J]. Mol Ther,2014,22(11):1992-2003.
[31] Stewart VA,McGrath SM,Dubois PM,et al. Priming with an adenovirus 35-circumsporozoite protein(CS)vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone[J]. Infect Immun,2007,75(5): 2283-2290.
[32] Tewari R,Spaccapelo R,Bistoni F,et al. Function of regionⅠ andⅡadhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity[J]. J Biol Chem, 2002,277(49):47613-47618.
[33] Pattnaik P,Shakri AR,Singh S,et al. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175[J]. Vaccine,2007,25(5): 806-813.
[34] Pandey KC,Singh S,Pattnaik P,et al. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies[J]. Mol Biochem Parasitol,2002,123(1):23-33.
[35] Grimberg BT,Udomsangpetch R,Xainli J,et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein[J]. PLoS Med,2007, 4(12):e337. doi: 10.1371/journal.pmed.0040337.
[36] Gao XH,Yeo KP,Aw SS,et al. Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites[J]. PLoS Pathog,2008,4(7):e1000104. doi: 10.1371/journal.ppat.1000104.
[37] 陈华,杨恒林. 疟疾疫苗研究进展[J]. 中国病原生物学杂志, 2010,5(3):225-226,229.
[38] Tsuboi T,Tachibana M,Kaneko O,et al. Transmission-blocking vaccine of vivax malaria[J]. Parasitol Int,2003,52(1):1-11.
[39] Saul A,Fay MP. Human immunity and the design of multi-component,single target vaccines[J]. PLoS One,2007,2(9): e850. doi: 10.1371/journal.pone.0000850.